Delisting risk
FBLG · NASDAQ · Biotechnology

FibroBiologics (FBLG)

Develops allogeneic fibroblast therapies for diabetic foot ulcers and other chronic diseases.

$1.88
Pre-market−0.06 (−3.09%)
At close$1.94(−8.06%)

Something off on this page? Send us feedback.

Next report
Oct 30, 2026
estimated · in 57 days
EPS estimate
−$0.63
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported−$0.09−$2.80−$0.12−$0.13−$0.98−$1.33−$0.66Pending
Estimate−$0.10−$0.11−$0.11−$0.10−$1.44−$1.26−$0.93−$0.63
Surprise+10.0%−2,445.5%−9.1%−30.0%+31.9%−5.6%+29.0%

RevenueReportedEstimate

Mar '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Oct 2026−$0.63
Jul 2026−$0.93−$0.66+29.0%
Apr 2026−$1.26−$1.33−5.6%
Feb 2026−$1.44−$0.98+31.9%
Oct 2025−$0.10−$0.13−30.0%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Jul 2025
May 2025
Mar 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Oct 30, 2026−$0.63
Jul 31, 2026−$0.93−$0.66+29.0%−2.7%
Apr 30, 2026−$1.26−$1.33−5.6%+10.6%
Feb 24, 2026−$1.44−$0.98+31.9%−1.5%
Oct 31, 2025−$0.10−$0.13−30.0%+0.3%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Jul 31, 2025
May 14, 2025
Mar 31, 2025
Mar 27, 2025
Nov 12, 2024
Aug 7, 2024
May 14, 2024
Feb 29, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 29, 2022
Jun 30, 2022
Mar 31, 2022